Table 2.
Crude and Adjusted Odds Ratios of NAFLD According to 24-Hour Urinary Sodium Excretion
| Variable | Crude | Adjusted model | |||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Total population (n=10,036) | |||||
| T1 | Reference | Reference | |||
| T2 | 1.40 (1.27–1.56) | <0.001 | 1.25 (1.09–1.43) | 0.001 | |
| T3 | 2.28 (2.06–2.52) | <0.001 | 1.46 (1.27–1.66) | <0.001 | |
| Sarcopenia absence (n=8,464)* | |||||
| T1 | Reference | Reference | |||
| T2 | 1.49 (1.32–1.67) | <0.001 | 1.46 (1.27–1.69) | <0.001 | |
| T3 | 2.33 (2.07–2.61) | <0.001 | 2.10 (1.82–2.42) | <0.001 | |
| Sarcopenia presence (n=1,157)* | |||||
| T1 | Reference | Reference | |||
| T2 | 1.04 (0.80–1.35) | 0.775 | 1.02 (0.75–1.39) | 0.892 | |
| T3 | 1.77 (1.37–2.29) | <0.001 | 1.68 (1.24–2.29) | 0.001 | |
Adjusted model: adjusted for age, sex, exercise, smoking, body mass index, hypertension, diabetes, dyslipidemia, aspartate aminotransferase†, alanine aminotransferase†, homeostasis model assessment of insulin resistance†, vitamin D, estimated glomerular filtration rate, Chronic Kidney Disease Epidemiology Collaboration, and appendicular muscle mass.
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval; T1, lowest tertile, T2, middle tertile; T3, highest tertile.
*In subgroup analysis by sarcopenia, appendicular muscle mass was excluded in the adjusted model; †Log-transformed.